NMDA receptor modulators and uses thereof
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
1. A method for treating neuropathic pain in a patient in need thereof comprising administering to the patient an effective amount of a compound represented by Formula I:
or a pharmaceutically acceptable salt, a stereoisomer, or an N-oxide thereof; wherein
T is, independently for each occurrence, CR 4 R 4 ′, and n is 0, 1, 2 or 3;
A is optionally present and is phenyl or pyridine, wherein A is optionally substituted by one or more substituents selected from R a ;
R 1 is —C(O)—O—C 1 -C 4 alkyl;
R 3 and R 3 ′ are independently selected from the group consisting of H, halogen, hydroxyl, phenyl, C 1 -C 4 alkyl, amido, amine, and C 2 -C 4 alkenyl, wherein C 1 -C 4 alkyl, C 2 -C 4 alkenyl and phenyl are optionally substituted by one or more substituents selected from R a ;
R 4 and R 4 ′ are independently selected from the group consisting of H, halogen, hydroxyl, phenyl, C 1 -C 4 alkyl, amido, amine, C 1 -C 4 alkoxy and C 2 -C 4 alkenyl, wherein C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxy, and phenyl are optionally substituted by one or more substituents selected from R a ;
R 2 is selected from the group consisting of H, R 7 , S(O) 2 —C 1 -C 4 alkyl, C 1 -C 4 alkyl, hydroxyl, and phenyl, wherein C 1 -C 4 alkyl and phenyl are optionally substituted by one or more substituents selected from R a ;
R 5 is selected from the group consisting of H, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 2 -C 4 alkenyl, cyano, amino, phenyl, and hydroxyl, wherein C 1 -C 4 alkyl, C 2 -C 4 alkenyl and phenyl are optionally substituted by one or more substituents selected from R a ;
R 7 is selected from the group consisting of —C(O)—C 1 -C 4 alkyl and C(O)—O—C 1 -C 4 alkyl, wherein C 1 -C 4 alkyl is optionally substituted by 1, 2 or 3 substituents selected from R b ;
R a is selected, independently for each occurrence, from the group consisting of carboxy, hydroxyl, halogen, amino, phenyl, C 1 -C 4 alkyl, and C 1 -C 4 alkoxy;
R b is selected, independently for each occurrence, from the group consisting of carboxy, hydroxyl, halogen, amino, phenyl, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, and —NH—R c ; and
R c is selected, independently for each occurrence, from the group consisting of —C(O)—O—C 1 -C 4 alkyl and —C(O)—C 1 -C 4 alkyl.
2. The method of claim 1 , wherein R 3 is H.
3. The method of claim 1 , wherein R 2 is C(O)—C 2 -C 4 alkyl, and C 2 -C 4 alkyl is substituted at one carbon with NH 2 and another carbon with hydroxyl.
4. The method of claim 1 , wherein C 1 -C 4 alkyl is selected from the group consisting of methyl, ethyl, propyl, n-butyl and t-butyl.